<DOC>
	<DOCNO>NCT00637533</DOCNO>
	<brief_summary>Lumbar sympathetic block part standard care treat patient sympathetically-maintained pain ( e.g . complex regional pain syndrome reflex sympathetic dystrophy- RSD ) . In patient low extremity pain reduce abolish temporarily block sympathetic nerve lumbar sympathetic block . Patients respond transiently sympathetic block often choose potentially dangerous lumbar sympathetic block neurolytic agent , surgical sympathectomy , continue severe refractory debilitate pain risky invasive surgical procedure spinal cord electrical stimulation.. It hypothesize Botulinum Toxin Type A ( BTA ) inject lumbar sympathetic block provide extend sympathetic blockade thus pain relief . This pilot study aim see BTA use safely low extremity sympathetic block , might useful provide prolonged pain relief .</brief_summary>
	<brief_title>A Pilot Clinical Trial Sympathetic Blockade With Botulinum Toxin Type A Treat Complex Regional Pain Syndrome ( CRPS ) : Randomized , Double-Blind , Controlled , Crossover Trial .</brief_title>
	<detailed_description>Lumbar sympathetic block perform twice patient : standard practice 10 cc 0.5 % Bupivicaine 75 unit Botox 10cc 0.5 % Bupivicaine . These do random order investigator patient blind medicine receive . Two week pain return 75 % baseline receive second block . Lumbar sympathetic blockade standard fashion accomplish place IV patient . The patient place face fluoroscopy table . They prepped drape sterile fashion . Conscious sedation provide versed Fentanyl operating room monitoring blood pressure , pulse oximetry , ekg . The skin topicalize one cc 1 % Lidocaine . The L2 lumbar vertebral body identify fluoroscopic guidance 22 gauge 6 inch spinal needle place anterolateral border L2 vertebral body . The retroperitoneal space identify loss resistance technique . Correct needle position confirm radiographically appropriate spread medication verify inject 3 cc radio opaque contrast material . The needle aspirated verify intravascular . Ten cc Bupivicaine 0.5 % inject divide dose ensure safety . Between injection patient ask report ring ear tingle mouth . Subjects give form ask rate pain ( 0 10 0 pain 10 bad pain imaginable ) noon every day start one week injection continue feel pain return baseline two week whichever longer . Days analgesia primary endpoint study .</detailed_description>
	<mesh_term>Complex Regional Pain Syndromes</mesh_term>
	<mesh_term>Reflex Sympathetic Dystrophy</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Severe pain low extremity ( great 6/10 ) duration 6 month despite aggressive previous therapy include previous lumbar sympathetic block , previous trial least 4 different pain medication include least 2 follow : gabapentin , amitryptiline , desipramine , nortryptiline , imipramine , carbamazepine , valproic acid , mexiletine , oxcarbazepine , topiramate , lamotrigine , flecainide , zonisamide , venlafaxine levetiracetam . The severity pain must patient must perceive function low extremity compromise pain . Any neuromuscular disorder myasthenia gravis , eaton lambert , muscular dystrophy . Any ongoing legal action relate pain . Any ongoing disability claim . A history severe psychiatric disorder . History adverse reaction botulinum toxin . History botulism . Untreated infection . Coagulopathy . Concurrent use anticoagulant medication .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>